Apogee Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Apogee Therapeutics' 2025 annual report highlights positive clinical trial data for lead programs in atopic dermatitis and asthma, alongside significant capital raises to fund pipeline development.
NASDAQ
Apogee Therapeutics' 10-K filing summarizes the company's financial results for 2024 and highlights the clinical progress of its antibody programs targeting inflammatory and immunology indications.
NASDAQ
Apogee Therapeutics outlines its share structure, voting rights, and registration rights in its recent 10-K filing, providing investors with key details about its capital stock.